Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Ginkgo biloba extract improves cognition and overall condition after ischaemic stroke

Christina Lau
23 Nov 2018
Dr Yanxin Zhao speaking at VasCog 2018

Use of a ginkgo biloba extract on top of standard preventive treatment is shown to improve cognitive function and overall condition after acute ischaemic stroke. 

In a multicentre pilot study, patients aged ≥50 years (n=201) who had an ischaemic stroke 7–14 days before baseline were randomized to receive standard treatment for prevention of stroke recurrence with or without EGb 761, a ginkgo biloba extract taken three times daily, for 24 weeks.

“Results showed significant improvements in cognitive function, mainly in memory, language, orientation and processing speed, in the EGb 761 vs standard treatment group, as assessed by Montreal Cognitive Assessment [MoCA] and Hopkins Verbal Learning Test [HVLT],” reported investigator Dr Yanxin Zhao of Fudan University, Shanghai, China, at VasCog 2018.

“Eighty percent of patients in the EGb 761 group had very much or much improved overall condition, compared with 20 percent of patients in the standard treatment group [p<0.05]. Neuropsychiatric symptoms and stroke-related symptoms were very mild at baseline, and improved slightly and to similar degrees in both groups,” he continued. “EGb 761 was safe and well tolerated in the study.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.